flâneur

A Potential Dramatic Change in Treating Type 1 Diabetes - Jacobs School of Medicine and Biomedical Sciences - University at Buffalo

medicine.buffalo.edu · 788 words · saved by 1 readers

Paresh Dandona, MD, PhD, is senior author on a paper published in the New England Journal of Medicine. By Ellen Goldbaum Published September 6, 2023 BUFFALO, N.Y. — Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin. Those are the remarkable findings of a small University at Buffalo study reported in the New England Journal of Medicine and published online on Sept. 6. “Our findings from this admittedly small study are, nevertheless, so promising for newly diagnosed Type 1 diabetes patients that we are now absolutely focused on pursuing a larger study for a longer period of time,” says Paresh Dandona, MD, PhD, SUNY Distinguished Professor in the Department of Medicine, former chief of the Division of Endocrinology, Diabetes and Metabolism in the Jacobs School of Medicine and Biomedical Sciences at UB and senior author on the paper. A total of 10 patients at

A Potential Dramatic Change in Treating Type 1 Diabetes - Jacobs School of Medicine and Biomedical Sciences - University at Buffalo Your Privacy is Important To Us. Buffalo.edu uses cookies to help build a better website experience for our visitors. Learn more in our Privacy Policy . Okay Paresh Dandona, MD, PhD, is senior author on a paper published in the New England Journal of Medicine. A Potential Dramatic Change in Treating Type 1 Diabetes By Ellen Goldbaum Published September 6, 2023 BUFFALO, N.Y. - Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic,

related reading